Internal report # (b)(4).Product not yet returned for evaluation.Most likely underlying root cause: mlc-140- supplier manufacturing defect.Based on the post market review syr-pmr-100 and review of the fda's total product life cycle (tplc) - total device problems, for possible delay in administration of insulin.Reference - capa (b)(4).Note: manufacturer contacted customer on 6/25/2016 in a follow-up call to ensure that the replacement products resolved the initial concern; customer stated that they received the replacement product however they didn't start to use it yet.No symptoms or medical attention reported since the last call.
|